Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

Autor: Mi Ran Yun, Sun Min Lim, Byoung Chul Cho, Christopher Daly, John DaSilva, Min Hee Hong, Mi Ra Yu, Seong Gu Heo, YoungJoon Park, Jae Hwan Kim, Eun Ji Lee, You Won Lee, Seung Yeon Oh
Rok vydání: 2023
DOI: 10.1158/1078-0432.22489181
Popis: Cells were seeded on a 96-well plate and incubated with the REGN5093-M114, Control Ab-M114, and EGFR TKIs (osimertinib, lazertinib). Cell viability was measured after 5 days of REGN5093-M114 treatment and 3 days of capmatinib treatment via CellTiter-Glo. The curved graphs show the cell viability results for a single drug, and the bar-graphs show the cell viability for the combination of two drugs.
Databáze: OpenAIRE